Fate Therapeutics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Fate Therapeutics' 2026 proxy statement outlines director elections, auditor ratification, executive compensation, and a proposal to increase the 2022 Stock Option and Incentive Plan share reserve by 7 million shares.
NASDAQ
Fate Therapeutics will hold its annual stockholders meeting on May 29, 2025, to vote on director elections, auditor ratification, executive compensation, and amendments to the company's charter and stock option plan.
NASDAQ
Fate Therapeutics is holding its 2025 Annual Meeting of Stockholders to vote on key proposals, including increasing authorized common stock and amending the 2022 Stock Option and Incentive Plan.
NASDAQ
Fate Therapeutics announces its Annual Meeting of Stockholders to be held on June 7, 2024, outlining proposals including director elections, auditor ratification, executive compensation approval, officer exculpation, and stock plan amendment.
NASDAQ
DEF 14A: Fate Therapeutics Seeks Stockholder Approval for Officer Exculpation and Incentive Plan Changes
Fate Therapeutics is holding its annual meeting to vote on key proposals including director elections, auditor ratification, executive compensation, officer exculpation, and an amendment to the stock option and incentive plan.